로딩 중…
지수 로딩 중…
L&K Biomed Ltd.
156100· KOSDAQ· Health Care· Health Care Equipment & Services
₩3,415+0.89%
2026-08-04
Financials
Valuation Metrics
L&K Biomed Ltd.'s Market Cap is ₩763B. At end of 2025 it was ₩2897B. Ranked #1424 of 2,436 in KR market (top 58%), #807 of 1,649 on KOSDAQ (top 49%), #53 of 96 in Health Care Equipment & Services (top 55%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 76.33B KRW | KR#1,424/2,436 Sec#53/96 |
| Revenue | 39.53B KRW | KR#1,906/2,436 Sec#55/96 |
| Net Income | -8.13B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 111.70B KRW | KR#1,670/2,436 Sec#50/96 |
| Net Assets | 51.81B KRW | KR#1,848/2,436 Sec#57/96 |
| Employees | 81 | KR#1,786/2,436 Sec#68/96 |
| Value | ||
| P/B | 1.47x | KR#1,778/2,436 Sec#58/96 |
| P/S | 1.93x | KR#1,802/2,436 Sec#47/96 |
| EV/EBITDA | 96.15x | KR#1,461/2,436 Sec#46/96 |
| FCF Yield | -22.10% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -15.70% | KR#2,008/2,436 Sec#68/96 |
| ROA | -7.28% | KR#1,984/2,436 Sec#65/96 |
| Op. Margin | 2.44% | KR#1,302/2,436 Sec#48/96 |
| Revenue Growth | 6.82% | KR#1,083/2,436 Sec#53/96 |
| Earnings Growth | -283.49% | KR#1,557/2,436 Sec#53/96 |
| Financial Health | ||
| Debt Ratio | 215.61% | KR#1,812/2,436 Sec#82/96 |
| Total Debt | 25.54B KRW | KR#1,269/2,436 Sec#32/96 |
| FCF | -16.87B KRW | KR#1,862/2,436 Sec#73/96 |
| Cash | 8.98B KRW | KR#1,733/2,436 Sec#60/96 |
| Current Ratio | 1.64x | KR#1,198/2,436 Sec#65/96 |
| Net Debt/EBITDA | 17.14x | KR#1,397/2,436 Sec#48/96 |
| Performance | ||
| 1Y Return | -50.00% | KR#2,079/2,436 Sec#77/96 |
| 1M Return | -25.76% | KR#2,316/2,436 Sec#92/96 |
| From 52W High | -79.18% | KR#2,342/2,436 Sec#93/96 |
| 1Y MDD | -82.41% | KR#2,335/2,436 Sec#92/96 |
| Trading | ||
| Volume | 287,330 shares | KR#418/2,436 Sec#16/96 |
| Foreign Own. | 8.13% | KR#559/2,436 Sec#16/96 |
| Per Share | ||
| EPS | -352 KRW | KR—/2,436 Sec—/96 |
| BPS | 2,652 KRW | KR#1,879/2,436 Sec#58/96 |
Company Info
동사는 2008년 척추 임플란트 개발, 제조, 판매를 시작으로 현재 6개의 비상장 종속회사를 보유하고 있음. 정형외과와 신경외과의 척추고정장치 및 척추 수술용 제품 설계, 개발, 제조, 판매를 주요 사업으로 하고 있으며, 경추용과 흉요추용 제품 라인업을 갖추고 있음. 척추 전문 임플란트 기술 및 연구개발 노하우를 바탕으로 Pectus Bar System 개발을 완료하고 FDA 허가를 받아 흉부임플란트 분야로 확장하고 있음. 엘앤케이바이오는 2008년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.